138 related articles for article (PubMed ID: 37917641)
1. PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
Chan LH; Wang P; Abuhammad S; Lim LRJ; Cursons J; Sheppard KE; Goode DL
PLoS One; 2023; 18(11):e0292278. PubMed ID: 37917641
[TBL] [Abstract][Full Text] [Related]
2. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
3. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
[TBL] [Abstract][Full Text] [Related]
4. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract][Full Text] [Related]
5. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Gerhart SV; Kellner WA; Thompson C; Pappalardi MB; Zhang XP; Montes de Oca R; Penebre E; Duncan K; Boriack-Sjodin A; Le B; Majer C; McCabe MT; Carpenter C; Johnson N; Kruger RG; Barbash O
Sci Rep; 2018 Jun; 8(1):9711. PubMed ID: 29946150
[TBL] [Abstract][Full Text] [Related]
6. SRSF3 and HNRNPH1 Regulate Radiation-Induced Alternative Splicing of Protein Arginine Methyltransferase 5 in Hepatocellular Carcinoma.
Wen C; Tian Z; Li L; Chen T; Chen H; Dai J; Liang Z; Ma S; Liu X
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499164
[TBL] [Abstract][Full Text] [Related]
7. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Tamiya H; Kim H; Klymenko O; Kim H; Feng Y; Zhang T; Han JY; Murao A; Snipas SJ; Jilaveanu L; Brown K; Kluger H; Zhang H; Iwai K; Ronai ZA
J Clin Invest; 2018 Jan; 128(1):517-530. PubMed ID: 29227283
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive nanopore sequencing methodology deciphers the complete transcriptional landscape of cyclin-dependent kinase 4 (CDK4) in human malignancies.
Adamopoulos PG; Athanasopoulou K; Tsiakanikas P; Scorilas A
FEBS J; 2022 Feb; 289(3):712-729. PubMed ID: 34535948
[TBL] [Abstract][Full Text] [Related]
9. A methyl transferase links the circadian clock to the regulation of alternative splicing.
Sanchez SE; Petrillo E; Beckwith EJ; Zhang X; Rugnone ML; Hernando CE; Cuevas JC; Godoy Herz MA; Depetris-Chauvin A; Simpson CG; Brown JW; Cerdán PD; Borevitz JO; Mas P; Ceriani MF; Kornblihtt AR; Yanovsky MJ
Nature; 2010 Nov; 468(7320):112-6. PubMed ID: 20962777
[TBL] [Abstract][Full Text] [Related]
10. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Aggarwal P; Vaites LP; Kim JK; Mellert H; Gurung B; Nakagawa H; Herlyn M; Hua X; Rustgi AK; McMahon SB; Diehl JA
Cancer Cell; 2010 Oct; 18(4):329-40. PubMed ID: 20951943
[TBL] [Abstract][Full Text] [Related]
11. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
Nicholas C; Yang J; Peters SB; Bill MA; Baiocchi RA; Yan F; Sïf S; Tae S; Gaudio E; Wu X; Grever MR; Young GS; Lesinski GB
PLoS One; 2013; 8(9):e74710. PubMed ID: 24098663
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
14. PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Hamard PJ; Santiago GE; Liu F; Karl DL; Martinez C; Man N; Mookhtiar AK; Duffort S; Greenblatt S; Verdun RE; Nimer SD
Cell Rep; 2018 Sep; 24(10):2643-2657. PubMed ID: 30184499
[TBL] [Abstract][Full Text] [Related]
15. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Kim H; Kim H; Feng Y; Li Y; Tamiya H; Tocci S; Ronai ZA
Sci Transl Med; 2020 Jul; 12(551):. PubMed ID: 32641491
[TBL] [Abstract][Full Text] [Related]
16. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
17. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
18. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
20. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Radzisheuskaya A; Shliaha PV; Grinev V; Lorenzini E; Kovalchuk S; Shlyueva D; Gorshkov V; Hendrickson RC; Jensen ON; Helin K
Nat Struct Mol Biol; 2019 Nov; 26(11):999-1012. PubMed ID: 31611688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
